e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Cystic fibrosis: clinical problems, genetics and microbiology in children
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
A. Amaddeo, M. Bramuzzo, S. Saletta, F. Poli (Trieste, Gorizia, Italy)
Source:
Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Session:
Cystic fibrosis: clinical problems, genetics and microbiology in children
Session type:
Thematic Poster Session
Number:
1197
Disease area:
Airway diseases, Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Amaddeo, M. Bramuzzo, S. Saletta, F. Poli (Trieste, Gorizia, Italy). Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. Eur Respir J 2013; 42: Suppl. 57, 1197
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF)
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Annual Congress 2009 - Update on eosinophilic lung diseases
Year: 2009
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 1052-1053
Year: 2001
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 156
Year: 2001
Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis
Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020
Year: 2020
Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Risk factors for allergic bronchopulmonary aspergillosis in paediatric patients with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2008; 31: 36-42
Year: 2008
A new risk factor predicts ABPA in patients with cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015
Concurrent allergic bronchopulmonary aspergillosis and aspergilloma: is it a more severe form of the disease?
Source: Eur Respir Rev 2010 19: 261-263
Year: 2010
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis
Source: Eur Respir J 2003 Oct 01;22(4):592-595
Year: 2003
Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis
Source: International Congress 2016 – Molecular immunology of the lung
Year: 2016
Real-life experience of Omalizumab in adult Cystic Fibrosis patients with allergic severe asthma and Allergic Bronchopulmonary Aspergillosis
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis
Source: Eur Respir Rev 2010 19: 349-351
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept